Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
No open-market purchases or sales by Protara Therapeutics, Inc. insiders were filed in the last 90 days; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Protara Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +25 vs. Q3 2025
- Shares held
- 39.8M
- +13.6M (+52.0%) vs. Q3 2025
- Total value
- $212.3M
- +$98.3M (+86.3%) vs. Q3 2025
- New holders
- 32
- 46 more added
- Sold out
- 7
- 15 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 119 | $176.0M |
| Q1 2026 | 114 | $237.4M |
| Q4 2025 | 105 | $212.3M |
| Q3 2025 | 81 | $114.0M |
| Q2 2025 | 76 | $90.1M |
| Q1 2025 | 59 | $123.8M |
| Q4 2024 | 60 | $156.6M |
| Q3 2024 | 35 | $19.1M |
| Q2 2024 | 38 | $22.2M |
| Q1 2024 | 34 | $18.3M |
| Q4 2023 | 30 | $8.17M |
| Q3 2023 | 31 | $8.55M |
| Q2 2023 | 29 | $12.3M |
| Q1 2023 | 29 | $16.9M |
| Q4 2022 | 30 | $14.7M |
| Q3 2022 | 31 | $16.7M |
| Q2 2022 | 33 | $18.4M |
| Q1 2022 | 35 | $33.2M |
| Q4 2021 | 38 | $46.5M |
| Q3 2021 | 36 | $43.7M |
| Q2 2021 | 40 | $69.3M |
| Q1 2021 | 50 | $134.0M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Protara Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Integral Health Asset Management, LLC | 2,250,000 | $12.0M | 0.61% | +850,000+60.7% | Added |
| Vanguard Group Inc | 2,391,903 | $12.7M | 0.00% | +487,747+25.6% | Added |
| BlackRock, Inc. | 2,408,868 | $12.8M | 0.00% | +179,500+8.1% | Added |
| Velan Capital Investment Management LP | 2,834,652 | $15.1M | 8.79% | +695,652+32.5% | Added |
| Janus Henderson Group PLC | 5,141,616 | $27.4M | 0.01% | +910,285+21.5% | Added |
| StemPoint Capital LP | 0 | $0 | 0.00% | −363,666−100.0% | Sold out |
| J. Goldman & Co LP | 0 | $0 | 0.00% | −100,350−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −21,516−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −17,890−100.0% | Sold out |
| Los Angeles Capital Management LLC | 0 | $0 | 0.00% | −15,545−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −48−100.0% | Sold out |
| Wolverine Trading, LLC | – | – | – | – | Not filed |